Oral composition

Abstract

This invention provides an oral composition containing glucosinolates that exhibits desired effects such as maintaining and improving vitality, maintaining the health of the skin or mucous membranes, and promoting protein metabolism. [Solution] An oral composition containing glucosinolate and at least one selected from pyrroloquinoline quinone and garlic, and preferably further containing zinc and / or vitamins of the vitamin B group.

Description

Technical Field

[0001] The present invention relates to an oral composition containing glucosinolate.

Background Art

[0002] In recent years, various health foods have been developed and various materials used in health foods have been studied, against the background of the increasing interest in health.

[0003] For example, cruciferous plants contain glucosinolate as a characteristic component and have attracted attention as plants having health functionality. As a health food using this cruciferous plant, for example, a juice composition of a cruciferous plant rich in glucosinolate and having an excellent balance of vitamin C, color tone, flavor, etc. has been proposed (see, for example, Patent Document 1).

Prior Art Documents

Patent Documents

[0004]

Patent Document 1

Summary of the Invention

Problems to be Solved by the Invention

[0005] As described above, although some studies have been made on glucosinolate, few studies have been made on the combination of glucosinolate and other components.

[0006] An object of the present invention is to provide an oral composition containing glucosinolate and exhibiting a desired effect.

Means for Solving the Problems

[0007] As a result of diligent research to solve the above problems, the inventors of the present invention have found that the desired effect can be achieved by combining glucosinolate with at least one selected from pyrroloquinoline quinone and garlic, and have completed the present invention.

[0008] In other words, the present invention is as follows: [1] An oral composition characterized by containing a glucosinolate and at least one selected from pyrroloquinoline quinone and garlic. [2] The oral composition according to [1] above, further characterized by containing zinc. [3] The oral composition according to [1] or [2] above, further characterized by containing at least one vitamin from the vitamin B group. [4] An oral composition according to any one of the above [1] to [3], characterized in that it is a food composition. [5] An oral composition according to any one of [1] to [4] above, characterized in that it is a food selected from nutritional functional foods, foods with functional claims, and foods for specified health uses.

[0009] [6] An oral food containing vitamins and / or minerals, further comprising glucosinolate and at least one selected from pyrroloquinoline quinone and garlic. [7] The oral composition according to [6] above, characterized by containing zinc. [8] The oral composition according to [6] or [7] above, characterized by containing at least one vitamin from the vitamin B group. [9] The oral composition according to [8] above, characterized in that at least one of the vitamins in the vitamin B group is vitamin B1 or vitamin B6.

[10] An oral composition according to any one of the above [1] to [9], which is indicated to have one or more functions selected from maintaining or improving vitality, maintaining the health of the skin or mucous membranes, and promoting protein metabolism. [Effects of the Invention]

[0010] The oral composition of the present invention exhibits excellent effects such as maintaining and improving vitality, maintaining the health of the skin or mucous membranes, and promoting protein metabolism. [Modes for carrying out the invention]

[0011] The oral composition of the present invention is characterized by containing a glucosinolate and at least one selected from pyrroloquinoline quinone and garlic.

[0012] The oral composition of the present invention, through a combination of glucosinolate and at least one selected from pyrroloquinoline quinone and garlic, can activate mitochondria and increase adenosine triphosphate (ATP) production. As a result, it exhibits excellent effects such as maintaining and improving vitality, maintaining the health of the skin or mucous membranes, and promoting protein metabolism.

[0013] Here, ATP, which is energy, is necessary for cells to function. Approximately 90% of this ATP is produced by oxidative phosphorylation in mitochondria in almost all cells except red blood cells. Therefore, it is thought that promoting mitochondrial activity, which is a common energy production mechanism regardless of cell type, can lead to the maintenance and improvement of various cell functions. Specifically, these effects include maintaining and improving vitality, maintaining the health of the skin or mucous membranes, and promoting protein metabolism.

[0014] For example, neuronal cell death, a contributing factor to decreased vitality, is known to be induced by decreased mitochondrial activity (Kitagawa, Kazuo, et al. "Results and Clinical Applications of Neuronal Cell Death Research." Stroke 30.6(2008):862-868). Therefore, promoting mitochondrial activity is thought to help maintain and improve vitality.

[0015] Furthermore, it is known that in epidermal cells, promoting mitochondrial activity enhances the production of fibroblast growth factor (FGF) and epidermal growth factor (EGF) (Kazuhiko Honjo. "Cytological effects of plant fermented paste AO via mitochondria and antioxidant activity." Pharmacology and Therapeutics 45.7(2017):1141-1152.). Also, in airway epithelial cells, decreased mitochondrial activity is known to cause excessive mucin secretion (Aguilera-Aguirre, Leopoldo, et al. "Mitochondrial dysfunction increases allergic airway inflammation." The Journal of Immunology 183.8(2009):5379-5387.). Therefore, it is thought that promoting mitochondrial activity contributes to maintaining the health of the skin or mucous membranes.

[0016] Furthermore, it has been reported that promoting mitochondrial activity in muscle cells increases muscle mass (Sugimoto, Ken. "3. Mitochondrial function of skeletal muscle and the significance of Myokine in sarcopenia." Journal of the Japan Geriatrics Society 49.2(2012):199-202.). Therefore, it is thought that promoting mitochondrial activity contributes to promoting protein metabolism.

[0017] Therefore, the oral composition of the present invention can be used as an oral composition for maintaining and improving vitality, an oral composition for maintaining the health of the skin or mucous membranes, and an oral composition for promoting protein metabolism.

[0018] The following describes each component contained in the oral composition of the present invention. [Glucosinolate] The glucosinolates in the present invention are derivatives of glucose and amino acids and are organic compounds containing sulfur and nitrogen. Glucosinolates are contained, for example, in plants of the order Brassicales, and specifically, are contained in plants such as cabbage, broccoli, wasabi, kale, and maca of the family Brassicaceae. As the glucosinolates contained in the oral composition of the present invention, those extracted and purified from plants or chemically synthesized can be used, and commercially available products can also be used. Further, plants containing glucosinolates may be used as they are or processed by treatments such as grinding or extraction.

[0019] When using a plant extract as the glucosinolate, the extract may be in a liquid state, but can also be used in a paste form or a dry powder (extract powder). Examples of the solvent used for extraction include water; lower alcohols such as methanol, ethanol, isopropanol, and butanol; lower esters such as ethyl acetate and methyl acetate; acetone; and mixed solvents of these with water. Among these, water, ethanol, or aqueous ethanol is preferable, and ethanol or aqueous ethanol is particularly preferable, from the viewpoint of more effectively enjoying the effects of the present invention.

[0020] The glucosinolates of the oral composition of the present invention are not particularly limited, but from the viewpoint of more significantly demonstrating the effects of the present invention, it is particularly preferable to use benzyl glucosinolate.

[0021] The amount of glucosinolate can be measured using high performance liquid chromatography (HPLC method). As the column, for example, COSMOSIL 5C18-AR-II (250 mm × 4.6 mm) manufactured by Nacalai Tesque can be used. Further, as the mobile phase, an aqueous solution of 0.05 M ammonium acetate is used for solution A, methanol is used for solution B, and the measurement can be carried out under the conditions of a column temperature of 30°C, an injection volume of 10 μL, a flow rate of 1.0 ml / min, and a measurement wavelength of UV235 nm. The mobile phase conditions are, for example, the conditions shown in Table 1 below.

[0022] [Table 1]

[0023] [Pyrroloquinoline quinone] In the present invention, pyrroloquinoline quinone (hereinafter sometimes referred to as PQQ) may be an oxidized form represented by the following formula (1) (oxidized PQQ), or a reduced form represented by the following formula (2) (reduced PQQ).

[0024] [ka]

[0025] [ka]

[0026] Furthermore, the pyrroloquinoline quinone in the present invention may be in the form of a free form or a salt. Examples of pyrroloquinoline quinone salts include alkali metal salts, alkaline earth metal salts, and ammonium salts. The pyrroloquinoline quinone contained in the oral composition of the present invention can be extracted and purified from plants or fermented foods, or chemically synthesized, and commercially available products may also be used. Pyrroloquinoline quinone is found, for example, in plants such as parsley and bell peppers, and in fermented foods such as natto, tofu, and miso. Alternatively, plants or fermented foods containing pyrroloquinoline quinone may be used as is after being powdered or granulated. The extraction conditions are the same as those for glucosinolates described above. The amount of pyrroloquinoline quinone can be measured using high-performance liquid chromatography (HPLC).

[0027] [Garlic] Garlic is a plant belonging to the genus Allium in the family Amaryllidaceae, and in this invention, it is preferable to use the bulb (scale bulb). Furthermore, in this invention, it is preferable to use garlic as, for example, a crushed product, juice, or extract. Examples of crushed products include dried powder and flaked products. The juice and extract may be in liquid form, but they can also be used as a paste or dried powder (juice powder, extract powder). The extraction conditions are the same as those for glucosinolate above.

[0028] The garlic used in this invention may be commercially available. For example, it may be raw garlic, dried garlic, or fermented garlic (black garlic), but fermented garlic is preferred from the viewpoint of particularly highlighting the effects of this invention. The method for producing fermented garlic is not particularly limited and known methods can be used. For example, raw garlic can be steamed and fermented for about 2 to 4 weeks at a temperature of about 30 to 70°C and a humidity of about 70 to 90%. As the microbial cells, microbial cells commonly used for fermentation, such as Aspergillus oryzae, yeast, lactic acid bacteria, acetic acid bacteria, and Bacillus subtilis, can be used.

[0029] The oral composition of the present invention preferably contains glucosinolate and at least one selected from pyrroloquinoline quinone and garlic, in addition to vitamins and / or minerals, and is particularly preferably zinc and vitamin B group vitamins.

[0030] (zinc) Zinc is a metallic element with the element symbol Zn and atomic number 30, and is also an essential element for humans. In this invention, there are no particular restrictions on the zinc as long as it can be taken orally, but examples include compounds such as inorganic salts and organic salts, and zinc-containing microorganisms. Examples of inorganic salts include sulfates, hydrochlorides, nitrates, and hydrotalcites, and examples of organic salts include salts of acetic acid, succinic acid, gluconic acid, and ascorbic acid. Examples of zinc-containing microorganisms include bacteria, microalgae, and yeast. In this invention, organic salts or zinc-containing microorganisms are preferred, and gluconates or zinc-containing yeast are particularly preferred. The amount of zinc can be measured using known analytical conditions, such as ICP analysis. Note that when the zinc of this invention exists as a salt, the amount of zinc in this invention refers to the amount of zinc itself and does not include the mass of compounds bound to the zinc.

[0031] (Vitamin B group) Examples of B vitamins used in this invention include vitamin B1, vitamin B2, vitamin B6, vitamin B12, niacin (vitamin B3), pantothenic acid (vitamin B5), folic acid (vitamin B9), and biotin (vitamin B7). In this invention, vitamin B1 and vitamin B6 are particularly preferred. The amount of vitamins can be measured, for example, using high-performance liquid chromatography (HPLC).

[0032] The oral composition of the present invention can be used, for example, as a pharmaceutical product (including quasi-drugs), a functional food such as a nutritional supplement, a functional food, or a food for specified health uses, for which efficacy claims have been approved by a designated institution, and other so-called health foods.

[0033] For example, since zinc and B vitamins are recognized as nutrients in functional foods, the oral composition of the present invention is useful as a functional food. Other nutrients in functional foods besides zinc and B vitamins include minerals such as potassium, calcium, and magnesium, and vitamins such as vitamin A, vitamin C, vitamin D, vitamin E, and vitamin K. The oral composition of the present invention can also be made into a functional food by adding these nutrients in addition to the components of the present invention (glucosinolate, pyrroloquinoline quinone, and / or garlic).

[0034] As described above, the oral composition of the present invention can be used as an oral composition for maintaining and improving vitality. Such an oral composition for maintaining and improving vitality is not particularly limited as long as it contains the components of the present invention (glucosinolate, and pyrroloquinoline quinone and / or garlic) and is distinguishable from other products in that it is used for maintaining or improving vitality. For example, any product in which the body, packaging, instructions, or promotional materials (advertising media) of the present invention displays the function of maintaining and improving vitality is included within the scope of the present invention.

[0035] Specifically, examples include health foods that display phrases such as "maintain vitality," "keep vitality up," "support daily vitality," "suppress decline in vitality," "for those concerned about vitality," "boost vitality," "increase vitality," "vitality," and "vitality." Furthermore, functional foods include those whose functionality is based on the scientific evidence of maintaining or improving vitality.

[0036] The oral composition for maintaining and improving vitality of the present invention may display the components of the present invention as active ingredients, but is not limited to products in which the components of the present invention are displayed as active ingredients on the product packaging, etc. For example, the active ingredient may not be specified, or only glucosinolate may be displayed as the active ingredient, or components other than glucosinolate may be displayed as the active ingredient. Furthermore, even general foods are included in the scope of the present invention if they are manufactured and sold with indications of their use. For example, foods that are sold with testimonials on websites, etc., mentioning the maintenance and improvement of vitality as personal impressions of people who have consumed them are also included in the scope of the present invention.

[0037] Similarly, the oral compositions of the present invention can be used as oral compositions for maintaining the health of the skin or mucous membranes. Such oral compositions for maintaining the health of the skin or mucous membranes are not particularly limited as long as they contain the components of the present invention (glucosinolates, and pyrroloquinoline quinone and / or garlic) and are distinguishable from other products in that they are used for maintaining the health of the skin or mucous membranes. For example, any product in which the body, packaging, instructions, or promotional materials (advertising media) of the present invention displays the function of maintaining the health of the skin or mucous membranes is included within the scope of the present invention.

[0038] Specifically, examples include health foods that display claims such as "helps maintain the health of skin and mucous membranes," "maintains skin health," "supports the maintenance of skin and mucous membrane health," "keeps skin healthy," "improves skin condition," "maintains moisture in mucous membranes," and "maintains the barrier function of skin and mucous membranes." Furthermore, functional foods include those whose functionality is based on the scientific evidence of maintaining the health of skin or mucous membranes.

[0039] The oral composition for maintaining the health of the skin or mucous membranes of the present invention may display the components of the present invention as active ingredients, but is not limited to products in which the components of the present invention are displayed as active ingredients on the product packaging, etc. For example, the active ingredient may not be specified, or only glucosinolate may be displayed as the active ingredient, or components other than glucosinolate may be displayed as the active ingredient. A nutritional functional food containing glucosinolate and pyrroloquinoline quinone and / or garlic, and which displays that vitamins or minerals help maintain the health of the skin or mucous membranes, is also included in the scope of the present invention. Furthermore, even general foods that are manufactured and sold with indications of their use are also included in the scope of the present invention. For example, foods that are sold with testimonials from people who have consumed them mentioning the maintenance of skin or mucous membrane health on a website, etc., are also included in the scope of the present invention.

[0040] Similarly, the oral compositions of the present invention can be used as oral compositions for promoting protein metabolism, and such oral compositions for promoting protein metabolism are not particularly limited as long as they contain the components of the present invention (glucosinolate, and pyrroloquinoline quinone and / or garlic) and are distinguishable from other products in that they are used for promoting protein metabolism. For example, any product that displays the function of promoting protein metabolism on the product itself, packaging, instructions, or promotional materials (advertising media) is included within the scope of the present invention.

[0041] Specifically, examples of health foods that display claims such as "supports protein absorption," "promotes muscle formation," "supports muscle maintenance," "keeps muscles healthy," "supports protein replenishment after exercise," "helps maintain muscle mass," and "contributes to maintaining health by being involved in protein metabolism" can be cited. Furthermore, functional foods include those whose scientific basis for functionality is the promotion of protein metabolism.

[0042] The oral composition for promoting protein metabolism of the present invention may display the components of the present invention as active ingredients, but is not limited to products in which the components of the present invention are displayed as active ingredients on the product packaging, etc. For example, the active ingredient may not be specified, or only glucosinolate may be displayed as the active ingredient, or components other than glucosinolate may be displayed as the active ingredient. A nutritional functional food containing glucosinolate and pyrroloquinoline quinone and / or garlic, and which displays that vitamins or minerals are involved in protein metabolism and contribute to maintaining health, is also included in the scope of the present invention. Furthermore, even general foods are included in the scope of the present invention if they are manufactured and sold with indications of their use. For example, foods that are sold with testimonials from people who have consumed them mentioning the promotion of protein metabolism are also included in the scope of the present invention.

[0043] Examples of the oral composition of the present invention include tablets, capsules, powders, granules, liquids, granules, rods, plates, blocks, solids, rounds, pastes, creams, caplets, gels, chewable tablets, sticks, and the like. It may also be in the form of ice cream, jelly, cookies, cakes, chocolates, bottled beverages, etc. Among these, the forms of tablets, capsules, powders, granules, rounds, and chewable tablets are preferred, with tablets being particularly preferred.

[0044] When the oral composition of the present invention is made into tablets, pills, or chewable tablets, it is preferable to add one or more of the following: excipients, lubricants, and fluidizers. This improves moldability and enhances the storage stability of the manufactured product. In particular, the use of excipients and lubricants can further improve storage stability.

[0045] The amount of glucosinolate in the oral composition of the present invention may be appropriately included within the range that provides the desired effect. For example, it is preferable that the oral composition of the present invention contains 0.001 to 50% by mass of glucosinolate on a dry weight basis, more preferably 0.005 to 20% by mass, and even more preferably 0.01 to 10% by mass.

[0046] The amount of pyrroloquinoline quinone in the oral composition of the present invention may be appropriately included within a range that achieves its effect. For example, the oral composition of the present invention preferably contains 0.001 to 50% by mass of pyrroloquinoline quinone on a dry weight basis, more preferably 0.005 to 20% by mass, and even more preferably 0.01 to 10% by mass.

[0047] The amount of garlic in the oral composition of the present invention may be appropriately included within a range that produces the desired effect. For example, the oral composition of the present invention preferably contains 0.001 to 50% by mass of garlic on a dry weight basis, more preferably 0.005 to 20% by mass, and even more preferably 0.01 to 10% by mass.

[0048] In the oral composition of the present invention, if zinc is included, the amount may be appropriately included within a range that achieves its effect. For example, it is preferable that the oral composition of the present invention contains 0.001 to 50% by mass of zinc on a dry weight basis, more preferably 0.005 to 20% by mass, and even more preferably 0.01 to 10% by mass.

[0049] In the oral composition of the present invention, if vitamin B group vitamins are included, the amount may be appropriately included within a range that achieves the desired effect. For example, it is preferable that the oral composition of the present invention contains 0.001 to 50% by mass of vitamin B group vitamins on a dry weight basis, more preferably 0.005 to 20% by mass, and even more preferably 0.01 to 10% by mass.

[0050] Regarding the mass ratio of pyrroloquinoline quinone to glucosinolate, it is preferable that the ratio of glucosinolate to pyrroloquinoline quinone be 1:0.001 to 1000, more preferably 1:0.005 to 500, even more preferably 1:0.01 to 100, and particularly preferably 1:0.1 to 10, in order to better enjoy the effects of the present invention.

[0051] Regarding the mass ratio of garlic to glucosinolate, in order to better enjoy the effects of the present invention, a glucosinolate:garlic ratio of 1:0.001 to 1000 is preferred, more preferably 1:0.005 to 500, even more preferably 1:0.01 to 100, and particularly preferred 1:0.1 to 10.

[0052] In the composition of the present invention, if zinc is included, the mass ratio of zinc to glucosinolate is preferably 1:0.001 to 1000, more preferably 1:0.005 to 500, even more preferably 1:0.01 to 100, and particularly preferably 1:0.1 to 10, in order to better enjoy the effects of the present invention.

[0053] In the composition of the present invention, when vitamin B group vitamins are included, the mass ratio of vitamin B group vitamins to glucosinolate is preferably 1:0.001 to 1000, more preferably 1:0.005 to 500, even more preferably 1:0.01 to 100, and particularly preferably 1:0.1 to 10, in order to better enjoy the effects of the present invention.

[0054] The daily intake of the components of the present invention (glucosinolate, pyrroloquinoline quinone, and / or garlic) for adults is not particularly limited, but from the viewpoint of enjoying the effects of the present invention, it is preferably 0.0001 to 100 mg, more preferably 0.001 to 50 mg, even more preferably 0.005 to 10 mg, and particularly preferably 0.01 to 1 mg in terms of dry mass.

[0055] Furthermore, in order to better enjoy the effects of the present invention when zinc is included, the daily intake of zinc for adults according to the present invention is preferably 0.001 to 100 mg, more preferably 0.01 to 50 mg, even more preferably 0.05 to 30 mg, and particularly preferably 0.1 to 20 mg, based on dry weight.

[0056] Furthermore, when the present invention contains B vitamins, the effects of the present invention can be more fully enjoyed. Therefore, the daily intake of B vitamins of the present invention for adults is preferably 0.001 to 100 mg, more preferably 0.01 to 50 mg, even more preferably 0.05 to 10 mg, and particularly preferably 0.1 to 5 mg, based on dry weight.

[0057] The oral composition of the present invention can be contained in one container, or divided into, for example, two or three containers, to represent one day's intake, so that the daily intake amount is the aforementioned intake.

[0058] The oral composition of the present invention may be prepared by known methods, with the addition of other components besides the components of the present invention as needed. Examples of other components include various excipients, binders, glossing agents, lubricants, stabilizers, diluents, fillers, thickeners, emulsifiers, antioxidants, pH adjusters, colorants, fragrances, and additives. [Examples]

[0059] <Test 1: Mitochondrial Activation Test> We confirmed the mitochondrial activation ability of the oral composition of the present invention in myoblast cell line (C2C12).

[0060] [Test substance] The following substances were used as test materials. • Glucosinolate: Commercially available benzyl glucosinolate (manufactured by Tokyo Chemical Industry Co., Ltd.) was used. • Pyrroloquinoline quinone: Commercially available pyrroloquinoline quinone disodium salt (manufactured by Shandong Jincheng Biomedical Co., Ltd.) was used. • Garlic (fermented garlic): Commercially available black garlic extract powder (manufactured by Sanct) was used. • Zinc: Zinc gluconate food additive (containing 12.9g of zinc per 100g of product) (manufactured by Tomita Pharmaceutical Co., Ltd.) was used. • Vitamin B group: Commercially available vitamin B1 (vitamin B1 hydrochloride) (manufactured by Kishida Chemical) and vitamin B6 (pyridoxine hydrochloride) (manufactured by Nacalai Tesque) were used.

[0061] (Preparation of test substance) Each test substance was dissolved in 0.5% DMSO-10% FBS-DMEM medium, sterilized by passing through a 0.2 μm filter, and obtained as a test substance preparation solution. Using each test substance preparation solution, a culture medium containing the test substance was prepared by mixing them in the mass ratios shown in Table 2 so that the total concentration of the test substance in the culture medium was 1 μg / mL.

[0062] [Test Method] 75cm in a 37℃, 5V %CO2 incubator 2 Mouse myoblasts (C2C12) were cultured in 10% FBS-DMEM using a flask. The cells were then suspended by trypsin and placed in each well of a 96-well plate (collagen-coated) at a rate of 8 × 10⁶ cells. 3 Cells were seeded at a cell density of cells / well and pre-cultured for 24 hours in a 37°C, 5V %CO2 incubator.

[0063] After removing the culture medium from each well, 100 μL / well of culture medium containing the test substance was added, and the mixture was incubated at 37°C in a 5V %CO2 incubator for 24 hours.

[0064] After 24 hours of incubation, the culture medium was removed, and each well was washed twice with serum-free DMEM. Then, 50 μL of 10 μM Rhodamine 123 (manufactured by Fujifilm Wako Pure Chemical Industries), prepared with serum-free DMEM, was added to each well. After standing for 30 minutes in a 37°C, 5V %CO2 incubator, the reagents were removed and each well was washed twice with 200 μL of PBS. After removing PBS from each well, 200 μL of PBS was added to each well, and the fluorescence intensity (excitation wavelength Ex. 507 nm, fluorescence wavelength Em. 529 nm) was measured. Based on the obtained data, mitochondrial activity (% of control) was calculated. Table 2 shows the relative values ​​with the Control (culture medium only) value set to 100.

[0065] %of control =(Data sample-Data blank) / (Data control-Data blank)×100

[0066] The denominator (baseline), "Data control - Data blank," is the value obtained by subtracting the fluorescence intensity of "blank" from the fluorescence intensity of the sample without the test substance (Control). On the other hand, the numerator, "Data sample - Data blank," is the value obtained by subtracting the fluorescence intensity of "blank" from the fluorescence intensity of the sample with the test substance added. Since the value obtained by subtracting the fluorescence intensity of blank from the fluorescence intensity of the sample is proportional to the amount of activated mitochondria, the calculated "% of control" serves as an indicator of mitochondrial activity.

[0067] [Table 2]

[0068] As shown in Table 2, the compositions of Examples 1 to 7, which contain the components of the present invention (glucosinolate, pyrroloquinoline quinone, and / or garlic), showed a synergistic improvement in mitochondrial activity compared to Comparative Examples 1 to 6, in which each test substance was added individually. In particular, compositions of Examples 3 to 7, which further contain zinc in addition to the components of the present invention, were found to yield high mitochondrial activity. Furthermore, compositions of Examples 5 to 7, which further contain B vitamins, showed even higher mitochondrial activity.

[0069] As described above, the oral composition of the present invention has been shown to have a high mitochondrial activation effect. Therefore, the oral composition of the present invention can be used to maintain and improve vitality, maintain the health of the skin or mucous membranes, and promote protein metabolism.

[0070] [tablet] After mixing the raw materials shown in Tables 3-5, tablets (oral composition for swallowing) with a tablet diameter of 8 mm and a dose of 300 mg per tablet were manufactured using a single-shot tablet press. Taking approximately 4 tablets per day yields effects such as maintaining and improving vitality, maintaining the health of the skin or mucous membranes, and promoting protein metabolism.

[0071] [Table 3]

[0072] [Table 4]

[0073] [Table 5] [Industrial applicability]

[0074] The oral composition of the present invention is industrially useful because it can be used as a health food or the like.

Claims

1. An oral composition characterized by containing glucosinolate and at least one selected from pyrroloquinoline quinone and garlic.

2. Furthermore, the oral composition according to claim 1, characterized in that it contains zinc.

3. Furthermore, the oral composition according to claim 2 is characterized by containing at least one vitamin from the vitamin B group.

4. An oral composition according to any one of claims 1 to 3, characterized in that it is a food selected from nutritional functional foods, foods with functional claims, and foods for specified health uses.

Images